Complete loss of HLA class I antigen expression on melanoma cells: A result of successive mutational events
Open Access
- 12 December 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 103 (6) , 759-767
- https://doi.org/10.1002/ijc.10906
Abstract
Alterations in the surface expression of HLA class I molecules have been described as a strategy of tumors to evade recognition by cytotoxic T cells. We detected complete loss of HLA class I antigen presentation for 2 tumor cell lines from 1 melanoma patient, the first originated from a regional lymph node lesion diagnosed simultaneously with the primary tumor and the second established 8 months later from a metastatic pleural effusion sample. Antigen presentation was not inducible with IFN‐γ but could be restored after transfection of tumor cells with b2m cDNA, indicating a defect in b2m expression. Analysis of the nature of this defect revealed that it originated from at least 2 mutational events affecting both copies of the b2m gene: a microdeletion of 498 bp in one b2m gene, including its entire exon 1, and a macrodeletion involving the entire copy of the second b2m gene. Microsatellite analysis pointed to the macrodeletion by demonstrating LOH for several specific markers on the long arm (q) of chromosome 15. Structural imbalance of 15q was verified by FISH. FISH studies also indicated the coexistence of a structurally abnormal variant of chromosome 15q with 2 apparently entire chromosomes 15q harboring the homozygous b2m microdeletion. Block of b2m expression in tumor cells builds a barrier to immunotherapy of cancer patients, and its early incidence should be of major consideration in the development and design of immunotherapeutic strategies.Keywords
Funding Information
- Verein zur Förderung der Krebsforschung in Deutschland
- European Commission (OISTER-QLG1-CT-2002-0068, ESTDAB-QLRT-2000-01325)
- Fondo de Investigaciones Sanitarias, Servicio Andaluz de Salud, Spain
This publication has 33 references indexed in Scilit:
- Defective death receptor signaling as a cause of tumor immune escapeSeminars in Cancer Biology, 2002
- The Interferon Inhibiting Cytokine IK is Overexpressed in Cutaneous T Cell Lymphoma Derived Tumor Cells That Fail to Upregulate Major Histocompatibility Complex Class II Upon Interferon-γ StimulationJournal of Investigative Dermatology, 2001
- Biological and clinical developments in melanoma vaccinesExpert Opinion on Biological Therapy, 2001
- Mutations of the β2‐microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptidesTissue Antigens, 1998
- beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.Journal of Clinical Investigation, 1998
- Implications for immunosurveillance of altered HLA class I phenotypes in human tumoursImmunology Today, 1997
- Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell lineTissue Antigens, 1996
- Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selectionEuropean Journal of Immunology, 1995
- Evidence for a shared HLA-A intralocus determinant defined by monoclonal antibody 131.The Journal of Experimental Medicine, 1985
- Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysisCell, 1978